(资料图片) 其他常规事件如财务报告发布已基于2025年三季报数据（营收8.92亿元，归母净利润2496.35万 元），但无公开信息提示近期有重大股东大会或产品发布等计划。 以上内容基于公开资料整理，不构成投资建议。 标签： 经济观察网 根据通化金马在投资者互动平台的最新披露，公司研制的化学1类新药琥珀八氢氨吖啶 片已完成综合审评工作，并进入最后审评环节，这一进展可能成为近期值得关注的事件。该信息由公司 于2026年2月12日通过官方渠道确认。 业绩经营情况 ...

其他常规事件如财务报告发布已基于2025年三季报数据（营收8.92亿元，归母净利润2496.35万元），但 无公开信息提示近期有重大股东大会或产品发布等计划。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 根据通化金马（000766）在投资者互动平台的最新披露，公司研制的化学1类新药琥珀八氢 氨吖啶片已完成综合审评工作，并进入最后审评环节，这一进展可能成为近期值得关注的事件。该信息 由公司于2026年2月12日通过官方渠道确认。 业绩经营情况 ...

证券日报网讯 2月12日，通化金马在互动平台回答投资者提问时表示，有关公司新药琥珀八氢氨吖啶片 上市申请审评中的重大节点信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 （文章来源：证券日报） ...

（文章来源：每日经济新闻） 每经AI快讯，通化金马（000766.SZ）2月12日在投资者互动平台表示，公司研制的化学1类新药琥珀八 氢氨吖啶片目前已完成综合审评工作，并已按要求提供各专业研究资料，进入最后审评环节，各项工作 进展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 ...

证券日报网讯2月9日，通化金马（000766）在互动平台回答投资者提问时表示，公司会在定期报告中披 露对应时点的股东人数信息，敬请关注。 ...

证券日报网讯 2月9日，通化金马在互动平台回答投资者提问时表示，公司研制的化学1类新药琥珀八氢 氨吖啶片目前已完成综合审评工作，并已按要求提供各专业研究资料，进入最后审评环节，各项工作进 展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。 （文章来源：证券日报） ...

Group 1 - The company has completed the comprehensive review of its new drug, a chemical Class 1 oral medication for Alzheimer's disease, and is currently in the final review stage [2] - The company has provided all required professional research materials as part of the approval process, and all work is progressing normally [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.05% on January 21, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Performers - The following companies showed significant gains: - Aoheng Pharmaceutical (002437) closed at 3.51, up 10.03% with a trading volume of 1.9852 million shares and a transaction value of 693 million yuan [1] - Guobang Pharmaceutical (605507) closed at 26.96, up 6.81% with a trading volume of 132,600 shares and a transaction value of 357 million yuan [1] - Laimei Pharmaceutical (300006) closed at 5.24, up 6.50% with a trading volume of 670,800 shares and a transaction value of 345 million yuan [1] Underperformers - The following companies faced notable declines: - Sunflower (300111) closed at 4.64, down 6.07% with a trading volume of 1.514 million shares and a transaction value of 708 million yuan [2] - Hanshang Group (600774) closed at 10.94, down 6.01% with a trading volume of 436,600 shares and a transaction value of 470 million yuan [2] - Huabang Health (002004) closed at 5.40, down 4.42% with a trading volume of 1.1395 million shares and a transaction value of 618 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 239 million yuan from institutional investors, while retail investors contributed a net inflow of 58.25 million yuan [2] - However, there was a net outflow of 297 million yuan from speculative funds [2] Individual Stock Capital Flow - Aoheng Pharmaceutical (002437) had a net inflow of 206 million yuan from institutional investors, accounting for 29.69% of its total trading [3] - Tonghua Golden Horse (000766) saw a net inflow of 74.79 million yuan from institutional investors, representing 14.69% [3] - Fuxing Pharmaceutical (600196) experienced a net inflow of 64.35 million yuan from institutional investors, making up 14.11% [3]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

Core Viewpoint - The report highlights the growth of industrial enterprises in Jilin Province, indicating a positive trend in the industrial sector with a year-on-year increase in the number of enterprises [1] Group 1: Company Information - Listed companies mentioned include Liyuan Co., Ltd. (002501), ST Jinhong (000669), Changchun Gas (600333), Quanyuan Spring (600189), Tonghua Jinma (000766), Xidian Pharmaceutical (301130), Jilin Carbon Valley (836077), Zhongyan Co., Ltd. (688716), Zhiyuan New Energy (300985), FAW Jiefang (000800), Jilin Expressway (601518), and Jilin Electric Power (000875) [1] Group 2: Industry Statistics - As of January-November 2025, the number of industrial enterprises in Jilin Province reached 3,539, an increase of 142 compared to the same period last year, representing a growth rate of 4.18% [1] - The proportion of Jilin's industrial enterprises accounts for 0.67% of the national total [1] Group 3: Research and Consulting - Zhiyan Consulting is identified as a leading industry consulting firm in China, specializing in deep industry research reports, business plans, feasibility studies, and customized services [1] - The firm emphasizes its commitment to providing comprehensive industry solutions to empower investment decisions [1]